Bellerophon Receives an Outperform from Cowen & Co.

By George MacDonald

Cowen & Co. analyst Ritu Baral maintained an Outperform rating on Bellerophon (NASDAQ: BLPH) today and set a price target of $10. The company’s shares opened today at $4.82.

Baral observed, “BLPH announced that the INOpulse in patients with PAH is on track to begin Ph3.”

Bellerophon has an analyst consensus of Hold.

The company has a one year high of $12.92 and a one year low of $2.75. Currently, Bellerophon has an average volume of 43.16k.

Unlike Cowen & Co.`s latest rating, based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is neutral on the stock. Earlier this month, Jonathan Peacock, a the President and CEO of BLPH bought 5,000 shares for a total of $27,350.

Baral is a top 100 analyst with an average return of 19.3% and a 46.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Protalix Biotherapeutics, Intra-Cellular Therapies, and Anthera Pharmaceuticals.

Bellerophon Therapeutics LLCis a clinical-stage therapeutics company developing products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary and cardiac diseases.